When you use our sites, PAREXEL will assign cookie files (“Cookies”) to you, which are a small amount of information we send to your web browser. Cookies enable the computers operating our websites to differentiate between visitors and to track the patterns of activities engaged in by different visitors. By clicking the Continue Browsing button or continuing to use this site, you agree to accept the PAREXEL Privacy Policy and all Cookies deployed on this site. You may choose to continue browsing with cookies, or leave the site.

Skip to main content

Regulatory & Access Resources

Home
COVID-19
Latest Content
Meet our experts
About us

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
Latest Content
The impact of COVID-19 on clinical trials in rare disease and oncology

The impact of COVID-19 on clinical trials in rare disease and oncology

Author Becky Hurt

Previous Article

We need faster endpoints for targeted cancer drugs, and there is one

As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how targeted cancer drugs can benefit patients. He believes it can be created by combining two...
Next Flipbook

Five competencies for operational excellence in cell and gene therapy clinical trials

What is different about cell & gene therapy trials, and what does it take to operationalize them effectively? We break it down into five competencies you need for success.

Other content in this Stream

Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Parexel communications experts celebrate #MedComms day by discussing how new guidelines and changes in the clinical trial space translate to medical communications and how Parexel plans to approach fu

Watch Video
Battling rare disease: personally and professionally

Lisa Dilworth – VP of Operations for Parexel Biotech Americas West, and Sarah Glass – Global Head of Rare Diseases for Parexel, share candidly about their personal journeys with rare diseases and the

Watch Video
The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief...

Learn More
We need faster endpoints for targeted cancer drugs, and there is one

As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how targeted cancer drugs can benefit patients. He believes it can be created by combining two...

Learn More
Five competencies for operational excellence in cell and gene therapy clinical trials

What is different about cell & gene therapy trials, and what does it take to operationalize them effectively? We break it down into five competencies you need for success.

View Now
Three ways to improve your chances that insurers will pay for a new CGT

When developing cell and gene therapies (CGTs), drug companies face significant hurdles. One of which is getting insurance companies to pay for these treatments that can potentially cure patients...

Learn More
How market exclusivities can affect your development program

Learn More
Parexel on the pulse

Parexel regulatory expert, Mark Birse, gives an update on BREXIT.

Watch Video
Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

Learn More
Virtual meetings are easy, right?

Recommendations for navigating the "new normal" and how to prepare for the future.

Learn More
Parexel on the Pulse

Paul Bridges on the EU Clinical Trial Regulation (CTR)

Watch Video
Five points to remember if FDA issues a Form 483

Learn More
Hong Kong Exchange: Nurturing China’s Biotech Valley

About the Authors Daniel Huang is an Analyst based in the Hong Kong...

Learn More
Crafting a genomics strategy early is key for successful oncology drug development

Discover three key considerations for crafting a successful genomic biomarker strategy in this article.

View Now
eBook: Biopharma in the COVID-19 World

Learn More
NMPA Guidance on the Management of Clinical Trials during the COVID-19 from July 2020

Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...

Learn More
Top 10 Myths About Working with the FDA for an Oncology Drug Approval

Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and commercial success at the earliest stage. In that respect, regulatory considerations figure...

Learn More
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...

Learn More
FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

Global manufacturers and regulators are facing new challenges during the SARS-CoV-2 pandemic to maintain supply chains, and avoid shortages, of drugs, biologics and medical devices. Numerous...

Learn More
Using risk assessment decision tree models to maintain safety and data validity in clinical trials during COVID-19

During the COVID-19 pandemic, challenges to the conduct of clinical trials may arise, e.g. due to travel restrictions or quarantines, interruptions to supply chains, or when site personnel or...

Learn More

Recommended For You

Return to Home